



## Resolution n° 13-2019-e

### Amendment to WHO Enabler Grant

Recalling Unitaid Board Resolutions 7-2016-e, 9-2017-e, 17-2017-e and 19-2017-e in which the Executive Board approved the commitment of funds of a total amount of up to US\$ 29,345,611 to WHO for the Enabler Grant (comprising the HIV/HCV, Malaria and TB Sub-Grants);

Noting the potential to further strengthen the impact of Unitaid's investments by leveraging the support of WHO for ongoing Board approved projects in the following two Areas for Intervention: (i) "Optimizing management of co-infections and co-morbidities in people living with HIV", approved in Board Resolution EB27/2017/R5; and (ii) "Accelerating adoption of innovative vector control tools" approved in Board Resolution EB23/2015/R3; and

Also acknowledging the need to increase the funding to WHO to cover additional support to several Unitaid projects which are already within the existing scope of the three Sub-Grants;

The Board authorizes, subject to availability of funds, the Executive Director to extend the duration of all WHO Enabler Sub-Grants until 31 December 2022 and to commit additional funding of US\$16,912,620 to be allocated across the three Sub-Grants as follows:

- US\$ 7,975,000 for HIV and Co-infections/Co-morbidities (previously referenced as HIV/HCV);
- US\$ 4,737,620 for Malaria; and
- US\$ 4,200,000 for TB.

The additional funding and extension to the grant duration is conditional upon signature of an amendment to the Enabler Grant Memorandum of Understanding between Unitaid and WHO reflecting the new duration and budget ceiling.

**Lead Organization:** WHO

**Revised Project Duration:** 1 June 2017 - 31 December 2022

**Revised total budget ceiling:** US\$ 46,258,231

Marisol Touraine  
Chair of the Unitaid Executive Board